Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy
NCT ID: NCT00978185
Last Updated: 2013-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
699 participants
INTERVENTIONAL
2008-11-30
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase III trial is studying acupressure wristbands to see how well they work compared with standard care in controlling nausea caused by chemotherapy.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care in the management of chemotherapy-induced (acute and delayed) nausea compared to patients receiving standard care with sham-acupressure wristbands and standard care alone.
Secondary
* To assess the cost effectiveness and extent of use of usual care in patients using acupressure wristbands in addition to standard care for the management of chemotherapy-induced nausea compared to patients receiving standard care with sham-acupressure wristbands and standard care alone.
* To assess the level of quality of life in patients using acupressure and standard care alone.
* To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care in the management of chemotherapy-induced (acute and delayed) vomiting compared to patients receiving standard care with sham-acupressure wristbands and standard care alone.
* To ascertain for which emetogenic level of chemotherapy regimens (i.e., high, moderate, or low emetogenic chemotherapy) self-acupressure using wristbands in addition to standard care is more or less effective in terms of nausea compared to patients receiving standard care with sham-acupressure wristbands and standard care alone.
* To ascertain whether any improvement in chemotherapy-induced nausea and vomiting from using acupressure wristbands is different in males and females.
* To ascertain whether there is an age effect from the use of acupressure wristbands in relation to chemotherapy-induced nausea and vomiting.
OUTLINE: Patients are stratified according to gender, age in years (16 to 24 vs \>24 to 50 vs \> 50), and level of emetogenic chemotherapy (high vs moderate vs low). Patients are randomized to 1 of 3 intervention arms:
* Arm I (acupressure group): Patients receive standard antiemetics comprising an oral 5-HT3 receptor antagonist (i.e., Zofran) and oral or IV dexamethasone before and for 3 days post-chemotherapy (for highly emetic chemotherapy); an oral 5-HT3 receptor antagonist (i.e., Zofran) and dexamethasone IV before chemotherapy and a 5-HT3 receptor antagonist or dexamethasone for 2 days post-chemotherapy (for moderately emetogenic chemotherapy); or oral dexamethasone before chemotherapy (for low-emetogenic chemotherapy). Beginning on the morning before chemotherapy, patients wear a pair of SeaBand™ elastic wristbands on each arm for 7 days. Each wristband has a 1-cm protruding round plastic button (stud) pressing the P6 acupoint, located on the anterior surface of the forearm, approximately three-finger width up from the crease of the wrist between the tendons of the Palmaris longus and flexor carpi radialis.
* Arm II (sham acupressure group): Patients receive standard antiemetics as in arm I. Beginning on the morning before chemotherapy, patients wear a pair of elastic wristbands on each arm for 7 days. Each wristband has a flat button pressing the P6 acupoint, located on the anterior surface of the forearm, approximately three-finger width up from the crease of the wrist between the tendons of the Palmaris longus and flexor carpi radialis.
* Arm III (control group): Patients receive standard antiemetics as in arm I. Patients are assessed periodically by questionnaires.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SUPPORTIVE_CARE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
medical chart review
questionnaire administration
acupressure therapy
quality-of-life assessment
sham intervention
standard follow-up care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of any cancer
* Scheduled to receive their first chemotherapy course
* Scheduled to receive highly, moderately, or low-emetogenic chemotherapy
* Scheduled to receive a chemotherapy regimen given as a single administration at the beginning of the course repeated in 3-week courses
* Currently receiving adjuvant chemotherapy as outpatient
* Acupressure wristband-naïve (in terms of never having tried such a wristband; may have seen or heard about such wristbands)
PATIENT CHARACTERISTICS:
* Able to perform self care (i.e., no inability to use wristbands appropriately or mental incapacity preventing continuous and optimal use of wristbands) as judged by the investigators
* No liver disease
* No metabolic risk factors for nausea (i.e., electrolyte imbalances causing nausea/vomiting)
* No mechanical risk factors for nausea (i.e., intestinal obstruction)
* No nausea and/or vomiting due to use of opioids
* No lymphedematous arms
* No chronic alcohol use
PRIOR CONCURRENT THERAPY:
* No concurrent radiotherapy
* No concurrent chemotherapy regimens as inpatients
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Manchester
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alex Molassiotis, MD
Role: PRINCIPAL_INVESTIGATOR
University of Manchester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Manchester
Manchester, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UM-ACMCN
Identifier Type: -
Identifier Source: secondary_id
EU-20971
Identifier Type: -
Identifier Source: secondary_id
CDR0000649812
Identifier Type: -
Identifier Source: org_study_id